-transparent.png){kind=logo}
From September 1979 to December 1983, a phase II trial with teniposide (VM-26) in multiple myeloma (MM) was conducted at our institution. Of the 30 patients entered, 25 were evaluable for response, 12 previously treated with M-2 protocol and 13 previously untreated elderly (greater than or equal to 70 years) patients. A median of nine cycles (range 1-21) of VM-26 was administered. Seven responses (28%) according to Myeloma Task Force criteria were observed with a median duration of 4 months (range 2-12+). Four responses (33%) were observed in the 12 previously treated patients. Overall toxicity was mild. VM-26 seems an active drug in MM, without significant toxicity even in elderly patients.
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
April 1992,
Seminars in oncology,
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
May 1989,
European journal of cancer & clinical oncology,
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
April 1992,
Seminars in oncology,
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
April 1988,
Investigational new drugs,
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
January 1980,
Cancer treatment reports,
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
April 1992,
Seminars in oncology,
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
August 1986,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
February 1991,
American journal of clinical oncology,
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
October 1984,
American journal of clinical oncology,
U Tirelli, and
A Carbone, and
V Zagonei, and
F Brema, and
A Veronesi, and
E Grigoletto, and
R Volpe
June 1992,
Experimental cell research,
